US Senators Urge PTO’s Vidal To Tackle Pharma Patent Thickets
Thickets Stifle Competition For Generic And Biosimilar Drugs
A bipartisan group of senators has written to the US Patent and Trademark Office, urging it to tackle the impact of patent thickets on the generic and biosimilar drug industries.
You may also be interested in...
A balanced policy environment that can support biosimilar competition is needed to allow the drugs to flourish in the US, says Amgen’s executive director of marketing and global biosimilars commercial lead Chad Pettit.
A balanced policy environment that supports competition is needed to allow biosimilars to flourish in the US, according to Amgen, along with strong and transparent IP processes to underpin continuing innovation in the biologics space. Chad Pettit, the firm’s executive director of marketing and global biosimilars commercial lead, talks to Generics Bulletin about the firm’s “unique perspective” on biosimilars.
A “lack of co-ordination” between the US FDA and PTO has allowed patent thickets to grow via the granting of flawed patents that do not meet legal requirements, senators Maggie Hassan and Bill Cassidy have complained.